Physician profile
Alla Katseva
NPI 1871547950
$395.77
in general payments reported to CMS, 2019-2025
15 companies · $58.95 in 2025
The $58.95 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.91 · 2022: $52.44 · 2023: $207 · 2024: $63.46 · 2025: $58.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.78 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $45.96 | 2022-2023 | Rexulti |
| Pfizer INC. | $45.44 | 2023 | |
| Axsome Therapeutics, INC. | $44.37 | 2023 | Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.14 | 2025 | Caplyta |
| Lilly USA, LLC | $30.88 | 2024 | Amyvid |
| Astrazeneca Pharmaceuticals Lp | $27.38 | 2023-2024 | Farxiga |
| Exact Sciences Corporation | $18.05 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $16.87 | 2023 | |
| Corium, LLC | $15.54 | 2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $13.91 | 2019 | |
| Cashflow Solutions, LLC | $13.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.69 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Katseva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.